The new pneumococcal vaccine

Clinical Microbiology and Infection

Volumn 8, Issue 10, 2002, Pages 623-633

  Obaro, S K ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Pneumococcal diseases; Protein conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID;

ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; HEALTH SURVEY; HUMAN; IMMUNOGENICITY; LICENSING; LOWER RESPIRATORY TRACT INFECTION; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; OTITIS MEDIA; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE B; MENINGOCOCCUS; PNEUMOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036805254     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00424.x     Document Type: Article

References (65)

1. . Watson DA, Musher DM, Jacobsen JW, Verhoef J. A brief history of the pneumococcus in biomedical research; a panoply of scientific discovery. Clin Infect Dis 1993; 17: 913-24.
2. Denny FW, Loda FA. Acute respiratory infections are the leading cause of death in children in developing countries. Am J Trop Med Hyg 1986; 35: 1-2.
3. World Health Organization. Vaccine research and development: report of the technical review group meeting, June 9-10, 1997. Geneva: WHO, 1997: 32-6.
4. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213-16.
5. Collignon PJ, Turnidge JD. Antibiotic resistance in Streptococcus pneumoniae. Med J Aust 2000; 173: S58-64.
6. Koomhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 1992; 15: 84-94.
7. Henrichsen J. Typing of Streptococcus pneumoniae: past, present, and future. Am J Med 1999; 26: 50S-54S.
8. Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J 1994; 11: 983-9.
9. Lloyd-Evans N, O'Dempsey TJ, Baldeh I et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 1996; 15: 866-71.
10. Huebner RE, Wasas A, Mushi A, Mazhani L, Klugman K. Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. Int J Infect Dis 1998; 3: 18-25.
11. Obaro SK, Adegbola RA. The pneumococcus: vaccines, carriage disease and conjugate vaccines. J Med Microbiol 2002; 2: 98-104.
12. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30: 100-21.
13. Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-6.
14. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981; 3: 246-53.
15. Centers for Disease Control. Prevention of pneumococcal disease: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(no. RR-8).
16. Scottish Centre for Infection and Environmental Health Surveillance Report: Respiratory Infections. SCIEH Weekly Report 2000; 34(4): 30-1.
17. Barraf LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12(5): 389-94.
18. Goetghebuer T, West TE, Wermenbol V et al. Outcome of meningitis caused by Streptococcus pneumomoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 2000; 3: 207-13.
19. Dowell SF, Butler JC, Giebink GS et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18: 1-9.
20. Austrian R, Howie VM, Ploussard JH. The bacteriology of pneumoccocal otitis media. John Hopkins Med J 1977; 141: 104-11.
21. Harrison CJ, Marks MI, Welch DF. Microbiology of recently treated acute otitis media compared with previously untreated acute otitis media. Pediatr Infect Dis 1985; 4(6): 641-6.
22. Shappart SM. Office visits for otitis media: United States, 1975-90. Vital Health Stat 1992; 214: 1-18.
23. Gates GA. Cost effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996; 114: 525-30.
24. Djuretic T, Ryan MJ, Miller E, Fairley CK, Goldblatt D. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect 1998; 37: 54-8.
25. Jokinen C, Heiskanen L, Juvonen H et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-88.
26. Walsh JA, Warren KS. Selective primary health care, an interim strategy for disease control in developing countries. N Engl J Med 1979; 301: 967-74.
27. Usen S, Adegbola R, Mulholland K et al. Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. Pediatr Infect Dis J 1998; 17: 23-8.
28. Ruuskanen O, Nohynek H, Ziegler T et al. Pneumonia in childhood: etiology and response to antimicrobial therapy. Eur J Clin Microbiol Infect Dis 1992; 11: 217-23.
29. Juven T, Mertsola J, Waris M et al. Etiology of community-acquired pneumonia in 254 hospitalised children. Pediatr Infect Dis J 2000; 19: 293-8.
30. Heiskonen-Kasma T, Korppi M, Jokinen C et al. Etiology of childhood pneumonia: serologic results in a prospective, population-based study. Pediatr Infect Dis J 1998; 17: 986-99.
31. Korppi M, Heiskanen-Kasma T, Jalonene C et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 1993; 152: 24-30.
32. Falade AG, Mulholland EK, Adegbola RA, Greenwood BM. Bacterial isolates from blood and lung aspirate cultures in Gambian children with lobar pneumonia. Ann Trop Paediatr 1997; 17: 315-19.
33. Adegbola RA, Obaro SK. Diagnosis of childhood pneumonia in the tropics. Ann Trop Med Parasitol 2000; 94: 197-207.
34. Shann F. Bacterial pneumonia: commoner than perceived. Lancet 2001; 357(9274): 2070-2.
35. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(suppl 1): S49-52.
36. Siber GR. Pneumoccal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385-7.
37. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococus pneumoniae infections among preschool children in the United States, 1978-94: implications for development of a conjugate vaccine. J Infect Dis 1995; 171: 885-9.
38. Steinhoff MC, Edwards K, Keyserling H et al. A randomised comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J 1994; 13: 368-72.
39. Kayhty H, Ahman H, Ronnberg P-R, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995; 172: 1273-8.
40. Leach A, Ceesay SJ, Banya WAS, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996; 15: 333-9.
41. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128: 649-53.
42. Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatriacs 1998; 101: 604-11.
43. 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis 1999; 18: 757-63.
44. Mbelle N, Wasas A, Huebner Kimura A, Chang I, Klugman K. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180: 1171-6.
45. Obaro SK, Adegbola RA, Chang I et al. Safety and immunogenicity of a nonavalent pneumococcal conjugate vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J 2000; 19: 463-9.
46. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997; 16: 1060-4.
47. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
48. Obaro SK, Huo Z, Banya WA et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997; 12: 1135-40.
49. O'Brien KL, Steinhoff MC, Edwards K, Keyserling H, Thoms ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996; 15: 425-30.
50. Obaro SK. Protein conjugate vaccines-how much is enough? Trends Microbiol 2001; 9: 364-5.
51. Vidarsson G, Sigurdardottir ST, Gudnason T et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998; 66: 2866-70.
52. Neiminen T, Kayhty H, Virolainen A, Eskola J. Circulating antibody secreting cell response to parenteral pneumoccal vaccines as an indicator of salivary IgA antibody response. Vaccine 1998; 16: 313-19.
53. Choo S, Zhang Q, Seymour L et al. Primary and booster salivary antibody responses to a 7-valent conjugate vaccine in infants. J Infect Dis 2000; 182: 1260-3.
54. Obaro SK, Adegbola RA, Banya WAS, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348: 271-2.
55. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
56. Advisory committee on immunization practices (ACIP). Preventing pneumococcal disease among infants and young children. MMWR 2000; 49 (RR-9): 1-35.
57. O'Brien KL, Winkelstein JA, Santosham M et al. Immunogenicity of a pneumococcal protein conjugate vaccine in infants with sickle cell disease. Pediatr Res 1996; 36: 160.
58. King JC, Vink PE, Farley JJ et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15: 192-6.
59. King JC, Vink PE, Farley JJ, Smilie M, Park M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997; 99: 575-80.
60. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999; 5: 336-45.
61. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000; 356: 1210-11.
62. Moulton LH, O'Brien KL, Kohberger R et al. Design of a group-randomized Streptococcus pneumoniae vaccine trial. Control Clin Trials 2001; 22: 438-52.
63. Dagan R, Melamed R, Muallem. M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996; 174: 1352-5.
64. Mulholland EK, Ogunlesi OO, Adegbola RA et al. Etiology of serious infections in young Gambian infants. Pediatr Infect Dis J 1999; 18(10 suppl): S35-41.
65. Wuorimaa T, Dagan R, Eskola J et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J 2001; 20: 272-7.